BOSTON SCIENTIFIC CORP (BSX.DE) Fundamental Analysis & Valuation

FRA:BSX • US1011371077

Current stock price

52.21 EUR
-1.25 (-2.34%)
Last:

This BSX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BSX.DE Profitability Analysis

1.1 Basic Checks

  • BSX had positive earnings in the past year.
  • BSX had a positive operating cash flow in the past year.
  • Each year in the past 5 years BSX has been profitable.
  • Each year in the past 5 years BSX had a positive operating cash flow.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • BSX has a better Return On Assets (6.64%) than 74.60% of its industry peers.
  • BSX's Return On Equity of 11.96% is fine compared to the rest of the industry. BSX outperforms 74.60% of its industry peers.
  • With a decent Return On Invested Capital value of 8.70%, BSX is doing good in the industry, outperforming 69.84% of the companies in the same industry.
  • BSX had an Average Return On Invested Capital over the past 3 years of 7.70%. This is below the industry average of 10.21%.
  • The 3 year average ROIC (7.70%) for BSX is below the current ROIC(8.70%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROIC 8.7%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • BSX's Profit Margin of 14.44% is amongst the best of the industry. BSX outperforms 82.54% of its industry peers.
  • In the last couple of years the Profit Margin of BSX has grown nicely.
  • Looking at the Operating Margin, with a value of 19.92%, BSX belongs to the top of the industry, outperforming 82.54% of the companies in the same industry.
  • BSX's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 69.01%, BSX belongs to the best of the industry, outperforming 80.95% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
Industry RankSector Rank
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BSX.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSX is still creating some value.
  • BSX has more shares outstanding than it did 1 year ago.
  • BSX has more shares outstanding than it did 5 years ago.
  • BSX has a better debt/assets ratio than last year.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • BSX has an Altman-Z score of 3.90. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
  • BSX has a better Altman-Z score (3.90) than 71.43% of its industry peers.
  • The Debt to FCF ratio of BSX is 3.13, which is a good value as it means it would take BSX, 3.13 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.13, BSX is in the better half of the industry, outperforming 74.60% of the companies in the same industry.
  • BSX has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • BSX has a Debt to Equity ratio (0.46) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Altman-Z 3.9
ROIC/WACC1.07
WACC8.11%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • BSX has a Current Ratio of 1.62. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • BSX has a Current ratio (1.62) which is comparable to the rest of the industry.
  • BSX has a Quick Ratio of 1.08. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.08, BSX is in line with its industry, outperforming 49.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.08
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BSX.DE Growth Analysis

3.1 Past

  • BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.51%, which is quite impressive.
  • Measured over the past years, BSX shows a very strong growth in Earnings Per Share. The EPS has been growing by 26.01% on average per year.
  • BSX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.88%.
  • Measured over the past years, BSX shows a quite strong growth in Revenue. The Revenue has been growing by 15.16% on average per year.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.13% on average over the next years. This is quite good.
  • BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.46% yearly.
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue Next Year10.8%
Revenue Next 2Y10.53%
Revenue Next 3Y10.36%
Revenue Next 5Y10.46%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. BSX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 20.00, the valuation of BSX can be described as rather expensive.
  • Based on the Price/Earnings ratio, BSX is valued a bit cheaper than 71.43% of the companies in the same industry.
  • BSX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.91.
  • The Price/Forward Earnings ratio is 17.48, which indicates a rather expensive current valuation of BSX.
  • Based on the Price/Forward Earnings ratio, BSX is valued a bit cheaper than 60.32% of the companies in the same industry.
  • BSX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.68.
Industry RankSector Rank
PE 20
Fwd PE 17.48
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • BSX's Enterprise Value to EBITDA ratio is in line with the industry average.
  • 60.32% of the companies in the same industry are more expensive than BSX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 24.79
EV/EBITDA 19.07
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of BSX may justify a higher PE ratio.
  • BSX's earnings are expected to grow with 13.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.37
PEG (5Y)0.77
EPS Next 2Y13.93%
EPS Next 3Y13.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BSX.DE Dividend Analysis

5.1 Amount

  • BSX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BSX.DE Fundamentals: All Metrics, Ratios and Statistics

BOSTON SCIENTIFIC CORP

FRA:BSX (4/9/2026, 7:00:00 PM)

52.21

-1.25 (-2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-22
Inst Owners94.17%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap77.47B
Revenue(TTM)20.07B
Net Income(TTM)2.90B
Analysts84.88
Price Target91.04 (74.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.84%
Min EPS beat(2)1.62%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)4.68%
Min EPS beat(4)1.62%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)5.56%
EPS beat(12)12
Avg EPS beat(12)5.7%
EPS beat(16)15
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.88%
Max Revenue beat(2)0.96%
Revenue beat(4)3
Avg Revenue beat(4)0.87%
Min Revenue beat(4)-0.88%
Max Revenue beat(4)2.43%
Revenue beat(8)7
Avg Revenue beat(8)1.73%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.59%
PT rev (1m)0%
PT rev (3m)-16.54%
EPS NQ rev (1m)-0.23%
EPS NQ rev (3m)-0.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.15%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)-0.56%
Valuation
Industry RankSector Rank
PE 20
Fwd PE 17.48
P/S 4.52
P/FCF 24.79
P/OCF 20
P/B 3.74
P/tB N/A
EV/EBITDA 19.07
EPS(TTM)2.61
EY5%
EPS(NY)2.99
Fwd EY5.72%
FCF(TTM)2.11
FCFY4.03%
OCF(TTM)2.61
OCFY5%
SpS11.56
BVpS13.95
TBVpS-0.61
PEG (NY)1.37
PEG (5Y)0.77
Graham Number28.62
Profitability
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROCE 10.46%
ROIC 8.7%
ROICexc 9.17%
ROICexgc 30.32%
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
FCFM 18.22%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
ROICexc(3y)7.95%
ROICexc(5y)7.36%
ROICexgc(3y)27.25%
ROICexgc(5y)24.65%
ROCE(3y)9.26%
ROCE(5y)8.51%
ROICexgc growth 3Y16.23%
ROICexgc growth 5Y30.87%
ROICexc growth 3Y13.89%
ROICexc growth 5Y25.4%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Debt/EBITDA 2.08
Cap/Depr 64.04%
Cap/Sales 4.36%
Interest Coverage 12.54
Cash Conversion 84.48%
Profit Quality 126.23%
Current Ratio 1.62
Quick Ratio 1.08
Altman-Z 3.9
F-Score7
WACC8.11%
ROIC/WACC1.07
Cap/Depr(3y)61.91%
Cap/Depr(5y)57.64%
Cap/Sales(3y)4.69%
Cap/Sales(5y)4.67%
Profit Quality(3y)127.68%
Profit Quality(5y)132.57%
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year10.8%
Revenue Next 2Y10.53%
Revenue Next 3Y10.36%
Revenue Next 5Y10.46%
EBIT growth 1Y30.81%
EBIT growth 3Y24.54%
EBIT growth 5Y34.7%
EBIT Next Year24.64%
EBIT Next 3Y16.7%
EBIT Next 5Y14.81%
FCF growth 1Y38.35%
FCF growth 3Y57.4%
FCF growth 5Y29.98%
OCF growth 1Y32.03%
OCF growth 3Y43.76%
OCF growth 5Y24.63%

BOSTON SCIENTIFIC CORP / BSX.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 5 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for BOSTON SCIENTIFIC CORP?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for BSX stock?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 20 and the Price/Book (PB) ratio is 3.74.


Can you provide the dividend sustainability for BSX stock?

The dividend rating of BOSTON SCIENTIFIC CORP (BSX.DE) is 0 / 10 and the dividend payout ratio is 0%.